Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label study of E7386 in advanced solid tumors including colorectal cancer
jRCT2080224589Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of e7386 in Nonhematologic neoplasms, colorectal cancer (CRC), small bowel cancer and 6 more (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Safety and tolerability of E7386. Started Mar 2019; status: completed.
02
Drugs
e7386
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)small bowel cancergastrointestinal neuroendocrine tumoraggressive fibromatosis (AF)
Beyond the preview
Go deeper on jRCT2080224589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224589.